Abstract:Background Multiple myeloma (MM) is an incurable disease that will eventually deteriorate. Chimeric antigen receptor (CAR) T cell therapy has been widely used in the treatment of hematological malignancy and showed a promising effect. BCMA (CD269) is exclusively expressed on the MM cells, making it an ideal target for immunotherapy. CD38 is highly expressed on the surface of MM cells, but is also expressed in immune cells and a minority of hematopoietic stem/ progenitor cells. Humanization reshaped antibody may reduce the potential risk of immunogenicity associated with the animal-derived antibodies. In this study, we constructed humanized BCMA CAR-T, CD38 CAR-T and bispecific BCMA/CD38 CAR-T, and explored their killing efficiency towards MM cells, providing the basis for clinical application. Methods Mouse anti-human BCMA and CD38 single chain fragment variable (scFv) sequences were obtained from previously established monoclonal antibody hybridoma cells (69G8 and HIT2) in our institution, respectively. The sequences were then humanized. Single-target CAR (BCMA CAR, CD38 CAR) and dual-target BCMA/CD38 CAR (LoopBC38 CAR) plasmids were constructed. Phenotype of CAR-T cells was detected. CAR-T cells and tumor cell lines were co-cultured in vitro, followed by the detection of the percentage of residual tumor cells, the degranulation and cytokine release level of T cells. Bone marrow mononuclear cells (BMMNC) from MM patients were co-cultured with CAR-T cells. MM cells were intravenously injected into immunodeficient mice, followed by CAR-T cell therapy. After co-culturing with peripheral blood mononuclear cells (PBMC) from healthy donors and CD34+ umbilical cord blood (UCB) stem cells, the proportion, cell subsets of residual cells and colony formation ability were assessed to verify the safety of CAR-T cells. Results The proliferation ability of CD38 CAR-T and LoopBC38 CAR-T was weaker than that of VEC-T and BCMA CAR-T. The residual H929 cells (BCMA+CD38+) after 48h cocultured with VEC-T and LoopBC38 CAR-T at E:T ratio of 1:1 was (20.82±9.773) % vs. (0±0) % (p<0.0001). After 48h at E:T ratio of 1:1, residual K562-BCMA cells (BCMA+CD38-) cocultured with CD38 CAR-T were (49.53±9.773) %, while that of LoopBC38 CAR-T were (8.49±4,766) % (p<0.0001). After 48h at E:T ratio of 1:4, residual Raji cells (BCMA-CD38+) were (62.69±22.2) % in BCMA CAR-T and (19.81±12.22) % in LoopBC38 group (p<0.01). The secretion level of cytokines such as IFN-γ, TNF-α, IL-2 was significantly higher in CAR-T cells than that of VEC-T cells. After co-cultured with H929, the IL-6 secretion level of LoopBC38 CAR-T cells was (7.28±0.4558) %, which was lower than that of CD38 CAR-T cells [(259.4±3.039) %, p<0.0001]. When cocultured with BMMNC derived from MM patients, BCMA CAR-T could kill BCMA+ cells, CD38 CAR T could kill CD38+ cells, while LoopBC38 CAR-T has both effects. In H929 xenograft NSG mice, the median survival time of MM mice was 35 days for VEC-T, 82 days for CD38 CAR-T. Until now, more than 50% mice are alive in BCMA CAR-T group and LoopBC38 CAR-T group, so they didn't reach the median survival time yet. LoopBC38 CAR-T did not significantly kill PBMC form healthy donors, with the residual PBMC cells after 24h co-culturing was (48.26±1.708) % in VEC-T and (49.0±2.517%) in LoopBC38 CAR-T (p>0.05), but had killing efficiency towards mononuclear-macrophages and NK cell. A slight killing effect on UCB CD34+ cells was observed in LoopBC38 CAR-T. The residual CD34+ cells in LoopBC38 CAR-T were (29.47±4.077) %, while that of VEC-T was (48.5±11.88) % (p>0.05). The number of CFU-GEMM in LoopBC38 CAR-T was (3.0±1.512) %, which was lower than that of VEC-T [(4.667±3.386) %, (p<0.001)]. Conclusion All CAR-T cells showed strong killing efficiency toward MM cells both in vitro and in vivo. Humanized BCMA CAR-T and CD38 CAR-T can specifically kill multiple myeloma cell lines and primary cells of patients. Bispecific CAR-T was able to target both antigens. CD38 CAR-T and bispecific CAR-T cells showed self-killing ability and altered their phenotypes. They can kill NK cells, mononuclear-macrophages in peripheral blood of healthy donor and have certain effects on the formation of CFU-GEMM, which may be a safety problem that requires further improvement for the application of CD38 CAR-T and bispecific BCMA/CD38 CAR-T cells.

Aptamer Ty04 Inhibits Multiple Myeloma Cell Growth Via Cell Cycle Arrest

Aptamer TY04 Inhibits the Growth of Multiple Myeloma Cells Via Cell Cycle Arrest

Triptolide Inhibits Transcription Factor Nf-Kappab and Induces Apoptosis of Multiple Myeloma Cells

4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways

MAPK Cascade Signaling is Involved in Α-Mmc Induced Growth Inhibition of Multiple Myeloma MM.1S Cells Via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis in Vitro.

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

[Proliferation-Inhibitory and Apoptosis-Inducing Effects of Targeting MTH1 on Multiple Myeloma Cells].

Screening and Characterization of an Annexin A2 Binding Aptamer That Inhibits the Proliferation of Myeloma Cells

Abstract 496: Targeting CD73-adenosine Axis for the Treatment of Multiple Myeloma

Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing P38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (Mapk)-Mediated G2/M Progression Delay and Cell Apoptosis

The Selective Activator Protein-1 Inhibitor T-5224 Regulates the IRF4/MYC Axis and Exerts Cooperative Antimyeloma Activity with Bortezomib

Clotrimazole inhibits growth of multiple myeloma cells in vitro via G0/G1 arrest and mitochondrial apoptosis

Effect of HM910, a Novel Camptothecin Derivative, on the Inhibition of Multiple Myeloma Cell Growth in Vitro and in Vivo.

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-KB signaling<i> in</i><i> vivo</i>

Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19

Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells.

Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma

Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28.

Aptamer Internalization Via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy.

The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma

Telomerase Inhibition And Cell Growth Arrest After Telomestatin Treatment In Multiple Myeloma